Please login to the form below

Not currently logged in
Email:
Password:

Boehringer’s Vargatef approved in the EU for lung cancer

Marks company’s second oncology drug to hit market
EU flag

Boehringer Ingelheim continued to build its oncology ambitions with European approval for a second lung cancer drug.

The European Commission granted marketing authorisation for Vargatef (nintedanib) in combination with docetaxal for use in adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) after first-line chemotherapy.

Prof Klaus Dugi, Boehringer's chief medical officer, said: “The approval of Vargatef expands our oncology portfolio, following last year's approval of Giotrif (afatinib) for another specific type of lung cancer.”

The launch of Giotrif/Gilotrif in 2013 as a treatment lung cancer patients who express epidermal growth factor receptor (EGFR) marked Boehringer's entry onto the oncology market.

The addition of Vargatef widens the potential patient base for the German company, allowing Boehringer to make sizeable inroads into lung cancer.

Vargatef, a triple angiokinase inhibitor, has impressed in clinical trials, including the LUME-Lung 1 clinical trial involving 1,314 patients with NSCLC.

The drug demonstrated that, compared to docetaxel alone, Vargatef extended median survival from 10.3 months to 12.6 months, with a 25.7% surviving for two years or more.

Nintedanib has also shown potential outside of cancer, recently being recommended for EU approval as a treatment for the rare lung condition idiopathic pulmonary fibrosis (IPF). The drug received US approval in this indication in October under the name Ofev.

Article by
Kirstie Pickering

28th November 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Complete Medical

Complete Medical delivers world-class solutions in medical communications, regulatory services, healthcare multichannel excellence, and strategic consultancy. We bring together specialist...

Latest intelligence

It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...
Louise Houson
30 Women Leaders in UK Healthcare
The enormous challenges facing UK healthcare mean it needs great leaders. PME’s Group Editor Andrew McConaghie introduces 30 outstanding innovators and trailblazers helping to shape the future...

Infographics